The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Convertible Note | Alive

About Wizray

Wizray develops pharmaceutical and chemical substance discrimination devices using near-infrared spectroscopy.

Wizray Headquarter Location

4th floor, Daiichi Central Building 6-36 Honmachi, Kita-ku

Okayama, 700-0901,


+81 086-800-1337

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Wizray

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Wizray is included in 1 Expert Collection, including Medical Devices.


Medical Devices

8,384 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

  • When was Wizray founded?

    Wizray was founded in 2019.

  • Where is Wizray's headquarters?

    Wizray's headquarters is located at 4th floor, Daiichi Central Building, Okayama.

  • What is Wizray's latest funding round?

    Wizray's latest funding round is Convertible Note.

  • Who are the investors of Wizray?

    Investors of Wizray include Hamamatsu Photonics, HOXIN and Setouchi Startups.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.